NCT01767636 2025-03-03
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Mayo Clinic
Phase 2 Completed
Clinical Trials
44 trialsNCT02207309 2024-08-09
Pazopanib Maintenance Phase II
Ludwig-Maximilians - University of Munich
Phase 2 Terminated
NCT00827372 2023-10-16
A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
Indiana University
Phase 2 Completed
NCT01462630 2022-08-19
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Fox Chase Cancer Center
Phase 2 Completed
NCT01498458 2022-06-10
PazoX
GBG Forschungs GmbH
Phase 1 Completed
NCT01157091 2022-06-08
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02357810 2022-06-07
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Northwestern University
Phase 2 Completed
NCT03334409 2022-03-31
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Terminated
NCT02212015 2022-03-22
EVA
Heidelberg University
Phase 2 Terminated
NCT01035658 2021-10-28
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
SCRI Development Innovations, LLC
Phase 1/2 Terminated
NCT01532687 2021-09-27
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01465659 2021-08-05
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
Northwestern University
Phase 1/2 Completed
NCT01610206 2021-02-25
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
University of Virginia
Phase 2 Completed
NCT02300545 2020-08-05
Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Washington University School of Medicine
Phase 2 Completed
NCT02193152 2020-07-14
Pazopanib in Molecularly Selected Patients With Advanced NSCLC
Washington University School of Medicine
Phase 2 Terminated
NCT01466972 2020-07-08
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
University of California, San Francisco
Phase 2 Completed
NCT01446809 2020-04-13
Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
University of Washington
Phase NA Completed
NCT01593748 2020-04-06
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
Medical University of South Carolina
Phase 2 Completed
NCT02795819 2019-10-24
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Virginia Commonwealth University
Phase 1 Terminated
NCT01184326 2019-10-02
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01107665 2019-08-07
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
University of California, Irvine
Phase 2 Completed
NCT02729194 2019-06-10
Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Completed
NCT01280201 2019-05-29
Pazopanib as Single Agent in Advanced NETs
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01253369 2019-04-23
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01832259 2018-12-12
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
University of Utah
Phase 2 Completed
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01158521 2018-09-12
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01394211 2018-07-26
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
University of Arizona
Phase 2 Terminated
NCT01361113 2018-04-25
Neoadjuvant Pazopanib in Renal Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01418001 2018-01-11
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT01012362 2017-12-28
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT01622660 2017-08-22
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01108055 2017-06-09
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Stanford University
Phase 2 Completed
NCT01599832 2017-06-08
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
University of Chicago
Phase NA Terminated
NCT01391611 2017-04-07
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
Stanford University
Phase 2 Terminated
NCT00800345 2017-03-28
Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors
Vector Oncology
Phase 1 Completed
NCT01262820 2017-03-07
LCCC0921
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01506596 2017-02-15
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
Vector Oncology
Phase 2 Completed
NCT01027598 2016-01-29
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01080248 2015-06-09
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT00731211 2015-05-20
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01049776 2014-09-19
GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
Illinois CancerCare, P.C.
Phase 2 Terminated
NCT00945477 2013-11-18
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
Illinois CancerCare, P.C.
Phase 2 Terminated